Dapagliflozin, advanced chronic kidney disease, and mortality: new insights from the DAPA-CKD trial
Nikolaus Marx, Jürgen Floege
Abstract
death -First HF hospitalisaon -Kidney outcome composite Effect of SGLT2 inhibitors in paents with CKD or HFrEF
Topics & Concepts
MedicineDapagliflozinKidney diseaseIntensive care medicineInternal medicineBenzhydryl compoundsDiabetes mellitusEndocrinologyType 2 diabetesOrganic chemistryChemistryBisphenol AEpoxyDiabetes Treatment and ManagementDiabetes Management and ResearchPancreatic function and diabetes